Symptomatology and risk factors present in SARS-CoV-2 disease
DOI:
https://doi.org/10.19230/jonnpr.4172Keywords:
symptoms; COVID-19; asymptomatic; hospitalized; risk factors for covid-19; vulnerability for covid-19Abstract
Objective. To analyze the information obtained from previous studies about the clinical picture present in SARS -CoV-2 disease, as well as the risk and vulnerability factors that predispose to this disease, in order to determine the most frequent ones in the interest of guiding the good diagnosis and treatment of the disease.
Method. A bibliographic review using the internet and search engines such as Google Scholar and PubMed. The reviewed sources are published in online journals such as Elsevier, Jama, SciELO, Science Direct, among others. Also included were documents published by the Mexican Ministry of Health, and the World Health Organization.
Results. It was observed that the symptomatology of SARS-CoV-2 is variable, asymptomatic cases were found. There is a high incidence of different symptoms such as: fever, dry cough, tiredness. COVID-19 has a 10.2% lethality in Mexico. Among the most common complications were found, pneumonia, heart failure. Several risk factors were observed that can lead to death as an outcome, such as: ATH, obesity, CVD, COPD, cancer and diabetes. In addition to these risk factors there are vulnerability factors such as: inadequate access to clean water and sanitation, inadequate infrastructure, food insecurity, among other.
Conclusions. The knowledge of the most common symptoms of SARS-CoV-2 disease is a clinically useful tool for improving health care. On the other hand, the presence of comorbidities leads to a significant worsening of the disease, risk and vulnerability factors point to the need for optimization of public health activities.
Downloads
References
Cronología de la respuesta de la OMS a la COVID-19 [Internet]. Who.int. 2020 [cited 10 October 2020]. Available from: https://www.who.int/es/news/item/29-06-2020-covidtimeline
Gal-Oz S, Maier B, Yoshida H, Seddu K, Elbaz N, Czysz C et al. ImmGen report: sexual dimorphism in the immune system transcriptome. Nature Communications. 2019;10(1).
Zheng Z, Peng F, Xu B, Zhao J, Liu H, Peng J et al. Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis. Journal of Infection. 2020;81(2):e16-e25.
Ortiz-Hernández L, Pérez-Sastré M. Inequidades sociales en la progresión de la COVID-19 en población mexicana. Revista Panamericana de Salud Pública. 2020;44:1.
Pérez Abreu M, Gómez Tejeda J, Dieguez Guach R. Características clínico- epidemiológicas de la COVID-19. Revista Habanera de Ciencias Médicas [Internet]. 2020 [cited 16 October 2020];19(2):1-15. Available from: https://dialnet.unirioja.es/servlet/articulo?codigo=7414176
López Ortiz E, Mazón Ramírez J. Cambios en el abordaje diagnóstico de COVID-19 en China. Atención Familiar [Internet]. 2020 [cited 16 October 2020];27(2):59. Available from: https://www.medigraphic.com/pdfs/atefam/af-2020/af202a.pdf
Coronavirus disease (COVID-19) [Internet]. World Health Organization (WHO). 2020 [cited 16 October 2020]. Available from: https://www.who.int/docs/default-
DIRECCIÓN DE INFORMACIÓN EPIDEMIOLÓGICA. 25° INFORME EPIDEMIOLÓGICO DE LA SITUACIÓN DE COVID-19. Ciudad de México: DIRECCIÓN DE INFORMACIÓN EPIDEMIOLÓGICA; 2020 p. 22.
Mortality Analyses - Johns Hopkins Coronavirus Resource Center [Internet]. Johns Hopkins Coronavirus Resource Center. 2020 [cited 17 October 2020]. Available from: https://coronavirus.jhu.edu/data/mortality
Jiang, X., Rayner, S. and Luo, M., 2020. Does SARS?CoV?2 has a longer incubation period than SARS and MERS?. Journal of Medical Virology, [online] 92(5), pp.476-478. Available at: <https://onlinelibrary.wiley.com/doi/epdf/10.1002/jmv.25708> [Accessed 16 October 2020].
Lauer, S., Grantz, K., Bi, Q., Jones, F., Zheng, Q., Meredith, H., Azman, A., Reich, N. and Lessler, J., 2020. The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application. Annals of Internal Medicine, [online] 172(9), pp.577-582. Available at: <https://www.acpjournals.org/doi/10.7326/M20-0504> [Accessed 16 October 2020].
Preguntas y respuestas sobre la enfermedad por coronavirus (COVID- 19) [Internet]. Who.int. 2020 [cited 16 October 2020]. Available from: https://www.who.int/es/emergencies/diseases/novel-coronavirus- 2019/advice-for-public/q-a-coronaviruses#:~:text=sintomas
Kim G, Kim M, Ra S, Lee J, Bae S, Jung J et al. Clinical characteristics of asymptomatic and symptomatic patients with mild COVID-19. Clinical Microbiology and Infection [Internet]. 2020 [cited 16 October 2020];26(7):948.e1-948.e3. Available from: https://www.clinicalmicrobiologyandinfection.com/action/showPdf? pii=S1198-743X%2820%2930268-8
Wiersinga W, Rhodes A, Cheng A, Peacock S, Prescott H. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19). JAMA [Internet]. 2020 [cited 16 October 2020];324(8):782. Available from: https://jamanetwork.com/journals/jama/fullarticle/2768391
Byambasuren O, Cardona M, Bell K, Clark J, McLaws M, Glasziou P. Estimating the extent of asymptomatic COVID-19 and its potential for community transmission: systematic review and meta-analysis. medRxiv [Internet]. 2020 [cited 16 October 2020];. Available from: https://www.medrxiv.org/content/10.1101/2020.05.10.20097543v3.article- info
Han C, Duan C, Zhang S, Spiegel B, Shi H, Wang W et al. Digestive Symptoms in COVID-19 Patients With Mild Disease Severity. American Journal of Gastroenterology [Internet]. 2020 [cited 16 October 2020];115(6):916-923. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172493/pdf/acg- publish_ahead_of_print-10.14309_ajg.0000000000000664.pdf
Docherty A, Harrison E, Green C, Hardwick H, Pius R, Norman L et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. BMJ [Internet]. 2020 [cited 16 October 2020];:m1985. Available from: https://pubmed.ncbi.nlm.nih.gov/32444460/
Long B, Brady W, Koyfman A, Gottlieb M. Cardiovascular complications in COVID-19. The American Journal of Emergency Medicine [Internet]. 2020 [cited 17 October 2020];38(7):1504-1507. Available from: https://www.ajemjournal.com/article/S0735-6757(20)30277-1/fulltext
Middeldorp S, Coppens M, Haaps T, Foppen M, Vlaar A, Müller M et al. Incidence of venous thromboembolism in hospitalized patients with COVID? 19. Journal of Thrombosis and Haemostasis [Internet]. 2020 [cited 17 October 2020];18(8):1995-2002. Available from: https://onlinelibrary.wiley.com/doi/full/10.1111/jth.14888
Chen Y, Shao S, Hsu C, Wu I, Hung M, Chen Y. Incidence of acute kidney injury in COVID-19 infection: a systematic review and meta-analysis. Critical Care [Internet]. 2020 [cited 17 October 2020];24(1). Available from: https://ccforum.biomedcentral.com/articles/10.1186/s13054-020-03009-y
Mao L, Jin H, Wang M, Hu Y, Chen S, He Q et al. Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China. JAMA Neurology [Internet]. 2020 [cited 17 October 2020];77(6):683. Available from: https://jamanetwork.com/
Rodriguez-Morales A, Cardona-Ospina J, Gutiérrez-Ocampo E, Villamizar- Peña R, Holguin-Rivera Y, Escalera-Antezana J et al. Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis. Travel Medicine and Infectious Disease [Internet]. 2020 [cited 17 October 2020];34:101623. Available from: https://www.sciencedirect.com/science/article/abs/pii/S1477893920300910? via%3Dihub
García Y, Padilla A, Blanco N. Caracterización de casos positivos y sospechosos de COVID-19 con comorbilidades [Internet]. Revfinlay.sld.cu. 2020 [cited 10 October 2020]. Available from: http://www.revfinlay.sld.cu/index.php/finlay/article/view/858
Simonnet A, Chetboun M, Poissy J, Raverdy V, Noulette J, Duhamel A et al. High Prevalence of Obesity in Severe Acute Respiratory Syndrome Coronavirus?2 (SARS?CoV?2) Requiring Invasive Mechanical Ventilation. Obesity. 2020;28(7):1195-1199.
N. Poshwa W. Is pregnancy a risk factor of COVID-19? [Internet]. European journal of obstetrics & gynecology and reproductive biology impact factor. 2020 [citado 15 octubre 2020]. Disponible en: https://www.ejog.org/article/S0301-2115(20)30433-4/fulltext
Hijona Elósegui, J, Carballo García A. ¿Existe transmisión materno-fetal del SARS-CoV-2 durante la gestación? [Internet]. US National Library of Medicine National Institutes of Health. 2020 [citado 15 octubre 2020]. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7274579/
Pallarés Carratalá V, Górriz-Zambrano C. COVID-19 y enfermedad cardiovascular y renal: ¿Dónde estamos? ¿Hacia dónde vamos? [Internet]. Science Direct. 2020 [citado 15 octubre 2020]. Disponible en: https://www.sciencedirect.com/science/article/pii/S1138359320301441
Salazar M, Barochiner J. COVID-19, hipertensión y enfermedad cardiovascular [Internet]. Science Direct. 2020 [citado 15 octubre 2020]. Disponible en: https://www.sciencedirect.com/science/article/pii/S1889183720300659#bib 0185
Lopez-Campos JL, Calle M. Soporte telefónico al paciente con EPOC en tiempos de la COVID-19 [Internet]. Science Direct. 2020 [citado 15 octubre 2020]. Disponible en: https://www.sciencedirect.com/science/article/pii/S2659663620300412
García N. Enfermedad Pulmonar Obstructiva Crónica (EPOC) y COVID-19 [Internet]. Libro Covid-19. 2020 [citado 15 octubre 2020]. Disponible en: https://angellockward.com.do/wp-content/uploads/2020/07/Libro-COVID- 19-FINAL-3-de-julio-2020-4.pdf#page=183
Zhang L, Zhu F. Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China [Internet]. National Center of Biotechnology Information. 2020 [citado 15 octubre 2020]. Disponible en: https://pubmed.ncbi.nlm.nih.gov/32224151/
Wiesner C. Investigación en cáncer en el contexto de la pandemia de la enfermedad por SARS-CoV-2 [Internet]. Scielo. 2020 [citado 15 octubre 2020]. Disponible en: http://www.scielo.org.co/scielo.php? script=sci_arttext&pid=S0120-41572020000200217
Protegiendo a los vulnerables [Internet]. Who.int. 2020 [cited 15 October 2020]. Available from: https://www.who.int/docs/default- source/coronaviruse/risk-comms-updates/update-25-vulnerable- populations-es.pdf?sfvrsn=43318be9_4
Published
Issue
Section
License
All accepted originals remain the property of JONNPR. In the event of publication, the authors exclusively transfer their rights of reproduction, distribution, translation and public communication (by any sound, audiovisual or electronic medium or format) of their work. To do so, the authors shall sign a letter transferring these rights when sending the paper via the online manuscript management system.
The articles published in the journal are freely used under the terms of the Creative Commons BY NC SA license, therefore.
You are free to:
Share — copy and redistribute the material in any medium or format
Adapt — remix, transform, and build upon the material
The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
NonCommercial — You may not use the material for commercial purposes.
ShareAlike — If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License
